Fresh from a meeting with drug makers, advocacy groups, and government agencies, World Health Organization officials say they are gradually moving closer to a framework for so-called fair pricing for prescription medicines.

Although recommendations are not yet forthcoming, the latest meeting builds on efforts that began a year ago and, at the time, identified several key issues to be addressed. A report by an informal advisory group last fall named transparency in pricing and research and development costs; the right of governments to issue compulsory licenses; manipulation of orphan drug designations; medicine shortages; and the merits of value-based pricing.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • When the industry argument first stresses the equivalent of ‘fraud and abuse,’ I’m not very hopeful. Then again, we have to start somewhere.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy